bluuebunny/crossref_metadata_2025_split huggingface dataset:
Recurrence of an undifferentiated pleomorphic pulmonary artery sarcoma 8 years after initial presentation: a case report
Authors: Bourlond Baudouin , Maurizi Niccolo , Antiochos Panagiotis , Skalidis Ioannis , Auf Der Springe Katarina , Royer Claire , Monney Pierre , Muller Olivier , Kirsch Mathias 
Published: June 2024

BackgroundPrimary cardiac tumors remain exceptionally rare, characterized by a poor prognosis. Among them, sarcomas originating in the pulmonary arteries constitute the most infrequent subgroup within primary cardiac sarcomas.Case summaryThis report presents the case of a 76-year-old female experiencing a recurrence of an undifferentiated pleomorphic intracardiac pulmonary artery sarcoma located in the right ventricular outflow tract, manifesting 8 years after initial remission. Successful outcomes were attained through a combination of surgical resection, state-of-the-art radiotherapy, and chemotherapy. This comprehensive approach proved essential for optimizing both survival and quality of life.DiscussionThe unexpectedly prolonged recurrence-free survival observed in this case underscores the effectiveness of the comprehensive multimodal treatment approach outlined in the existing literature. This highlights the pivotal role of a multidisciplinary strategy in addressing primary cardiac sarcomas, particularly those arising in the pulmonary arteries.
Metabolic syndrome and risk of subclinical hypothyroidism: a systematic review and meta-analysis
Authors: Zhong Lei , Liu Shuo , Yang Yao , Xie Tong , Liu Jifeng , Zhao Huahui , Tan Guang 
Published: June 2024

BackgroundSubclinical hypothyroidism (SCH) is a common endocrine subclinical disorder, the main adverse consequences of which are the development of clinical hypothyroidism and the promotion of ischemic heart disease. Metabolic syndrome (MetS) is a collection of metabolic problems. The goal of this meta-analysis was to evaluate the relationship between MetS and SCH.MethodsSuitable publications were identified using PubMed, Embase, and the Cochrane Library. The meta-analysis included only studies in English that reported odds ratio (OR) data for MetS and SCH. Two researchers combined data using a random-effects model. OR and 95% confidence intervals (CIs) were used to present the results.ResultsMetS was associated with an elevated risk of developing SCH (OR 2.56, 95% CI 1.44–4.55). However, the individual components of MetS were not associated with the risk of SCH. Subgroup analysis revealed that different definitions of MetS had varying effects on SCH. Sensitivity analysis confirmed that our results were robust.ConclusionsThis meta-analysis indicates that patients with MetS have an increased risk of SCH, while there is no significant association between the five individual components of MetS and the risk of SCH.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023454415.
A 6-year single-center prospective follow-up study of the efficacy of radiofrequency ablation for thyroid nodules
Authors: Chuanke Shi , Ming Luo , Zhideng Yan , Huan Liu 
Published: June 2024

BackgroundRadiofrequency ablation (RFA) is an alternative modality for thyroid nodules (TNs) and many studies have also confirmed its favorable efficacy and safety. The scope of RFA increases in clinical practice and the aim of our study was to evaluate the efficacy of RFA.MethodsWe conducted a prospective study to evaluate the efficacy of RFA for thyroid nodules between January 2017 and December 2022 at our institution. We assessed the change in nodal volume, volume reduction ratio (VRR), technique effective (TE) rate, complete ablation (CA) rate, and nodal regrowth rate and time after RFA.ResultsWe performed RFA for 1703 patients with TNs between January 2017 and December 2022, of which a total of 970 eligible patients were enrolled in the study. The preoperative volume of TNs was 6.23 ± 8.11ml, with 821 benign and 149 malignant nodules. The post-RFA TE and adjusted TE rate were 80% and 88.8%, respectively. CA was achieved in 145 (14.9%) patients with a mean time of 18.32± 12.98 months; nodal regrowth occurred in 15 (1.5%) patients with a mean time of 29.80 ± 12.47 months. TNs volume and VRR changed significantly at years 1 and 2 after RFA and stabilized after 5 years. A serious postoperative adverse event occurred in one patient with cervical sympathetic chain injury resulting in Horner’s syndrome. A transient or permanent damage of the recurrent laryngeal nerve could not be evaluated due to the lack of postoperative laryngoscopy, and this is a significant limitation of the study.ConclusionThe expanded RFA indications were also effective for TNs, with no significant change in long-term efficacy.
Activity of apremilast in a patient with severe pemphigus vulgaris: case report
Authors: Delvaux Cheyenne , Bohelay Gérôme , Sitbon Ishaï-Yaacov , Soued Isaac , Alexandre Marina , Cucherousset Joël , Gilardin Laurent , Diep Antoine , Caux Frédéric , Le Roux-Villet Christelle 
Published: June 2024

IntroductionAlthough the treatment for pemphigus vulgaris (PV) has been revolutionized by the use of rituximab combined with corticosteroids, new effective therapies with a better safety profile are needed.ObservationA 67-year-old woman was diagnosed with severe mucosal PV, which was initially misdiagnosed as atypical Behçet’s disease. Following an unsuccessful colchicine treatment, significant improvement was observed upon the introduction of apremilast: reduced pain, fewer lesions, and a stabilized weight. The discontinuation of apremilast led to a rapid relapse. Retrospective analysis through anti-Dsg3 ELISA indicated a gradual decrease in antibody levels during the apremilast treatment.DiscussionApremilast, a phosphodiesterase 4 inhibitor approved for psoriasis and Behçet’s disease’s related oral ulcers treatment, demonstrated its efficacy in this PV case. This is the second case report highlighting the effectiveness of apremilast for PV treatment. Apremilast’s ability to upregulate cyclic adenosine monophosphate (cAMP) levels appears to contribute to the stabilization of keratinocyte adhesion.ConclusionApremilast may be a promising therapeutic option for the treatment of pemphigus, with an innovative mechanism of action, no induced immunosuppression, and good tolerance. It could be a good alternative to steroids, in the treatment regimen of steroids combined with rituximab.
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL
Authors: Ricard Laure , Cervera Pascale , Stocker Nicolas , Corre Elise , Van de Wyngaert Zoé , Banet Anne , Marjanovic Zora , Dulery Rémy , Bravetti Clotilde , Joly Anne-Christine , Baylatry Minh Tam , Coppo Paul 
Published: June 2024

IntroductionAngioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by a T follicular helper cell phenotype expressing PD-1 (programmed cell death-1). AITL exhibits a poor response to conventional chemotherapy, with a median 5-year overall survival of 44% and a progression-free survival of 32%. Relapse is common, resulting in a median overall survival of 6 months. Recurrent mutations are detected in genes regulating DNA methylation, including TET2, DNMT3A, and IDH2 variants, along with the prevalent RHOA G17V mutation. In this context, patients treated with the hypomethylating agent 5-azacytidine achieved overall response and complete response rates of 75% and 41%, respectively. We hypothesized that targeted therapies combining anti-PD-1 checkpoint blockers with hypomethylating agents could be efficient in AITL patients and less toxic than standard chemotherapy.MethodsHere, we report the efficacy of a regimen combining 5-azacytidine and nivolumab in nine relapsed or refractory AITL patients.ResultsThis regimen was well-tolerated, especially in elderly patients. The overall response rate was 78%, including four partial responses (44%) and three complete responses (33%). Allogeneic hematopoietic stem cell transplantation was performed in two patients who reached complete response.DiscussionThese preliminary favorable results may serve as a basis for further investigation in prospective studies.
Effect of hypoxia on the post-hatching growth of the body of the fry and the caudal fin of the Atlantic Salmon (Salmo salar)
Authors: Rojas Mariana , Salvatierra Renato , Smok Carolina , Sandoval Cristian , Souza-Mello Vanessa , del Sol Mariano 
Published: June 2024

IntroductionHypoxia is a recurring problem in the fish farming industry. Currently, it is known that the exposure of fish and fry to a hypoxic environment induces important changes in their metabolism, compromising not only their development but also their reproduction and mortality rates. Our hypothesis is that hypoxia constitutes one of the etiological factors causing deformation of the body and caudal fin in this species, as well as affecting its growth.MethodsWe analyzed two hundred forty Salmo salar salmon fry, differentially cultured at 100% saturation (normoxia condition) and 60% (hypoxia condition) for 2, 4, 6, and 8 days, including a group under continuous hypoxia. We performed diaphanization and Alcian blue staining, along with standard histological techniques. The polyclonal anti-HIF-1a antibody was used as a marker of hypoxia in Salmo salar, and hypoxia in these fish was associated with the immunopositivity of this antibody.Results and discussionThe results indicate that there is an association between exposure to hypoxia and the deformation of the body and fin, as well as an agreement between hypoxia and the total length of the fry and fin. Several months after the event occurred, we were able to find and describe angiogenesis, blood vessel disorganization, and vasodilation histologically. Finally, hypoxic cells in the fry (HIF-1a) could be recognized and confirmed as hypoxia sensors. All of this indicates that hypoxia not only affects the fry during the development phase of the event, but that its results can be evident much later and affect the fry throughout their entire ontogeny.
Effects of vaccination against COVID-19 on overactive bladder symptoms on young population
Authors: de-la-Plaza-San-Frutos Marta , García-García Elisa , Martínez-Pascual Beatriz , Esteban Isabel Mínguez , Domínguez-Balmaseda Diego , Sosa-Reina M. Dolores 
Published: June 2024

IntroductionThe vaccines developed against COVID-19 have different modes of action, with a primary focus on the spike protein of the virus. Adverse effects following vaccination have been reported, including local and systemic symptoms. Understanding the potential side effects on the urinary tract after vaccination is of importance. Actively investigating and comprehending the potential impact on the urinary tract, we can enhance public health strategies and pave the way for safer and more effective vaccination programs.MethodologyThe study was based on an online survey that included the Spanish Version of the Overactive Bladder Symptom Score (OABSS-S); 2,362 men and women replied to the survey. After the application of the exclusion criteria, 1,563 participants were insured. In the context of COVID-19, individuals were questioned regarding several key factors related to their vaccination status and medical history. These factors included the number of vaccine doses received, the specific type of vaccine administered, whether they had previously contracted COVID-19, and the frequency of prior infections, if applicable.ResultsA total of 1,563 (74.7% women and 27.3% men) subjects between the ages of 18 and 45 completed the survey and were included in the final analyses. The most frequently administered vaccine type was Pfizer-BioNTech (42.2%), and most subjects received three doses. The proportion of females who received the AstraZeneca vaccine and do not require to urinate during the night is significantly higher compared to males (59.1% vs. 33.3%; p&lt;0.05). The proportion of individuals who urinate five or more times during the night is higher in those who have received a single vaccine dose than in those who have received three doses (2.2% vs. 0.1%; p&lt;0.05).ConclusionCOVID-19 vaccination has been found to impact the lower urinary tract (LUT) and overactive bladder (OAB). Initially, LUT symptoms worsened, and OABSS-S scores increased after the first vaccine dose in individuals under 45 years old. However, symptoms improved after receiving the third and fourth doses. Gender differences were observed in the vaccination effects. Men vaccinated with AstraZeneca reported a higher number of nighttime voids, while women vaccinated with Moderna reported more daytime voids.
Development and validation of a faecal immunochemical test-based model in the work-up of patients with iron deficiency anaemia
Authors: Hernández Goretti , Quintero Enrique , Morales-Arraez Dalia , Rayado Guillermo García , Hijos-Mallada Gonzalo , Fernández-Fernández Nereida , Castro-Parga Luisa de , Álvarez-Sánchez María Victoria , Olano Carolina , Rodríguez-Alcalde Daniel , Amaral-González Carla , Alonso-Abreu Inmaculada , Nicolás-Pérez David , Carrillo-Palau Marta , González-Dávila Enrique , Gimeno-García Antonio Z. 
Published: June 2024

ObjectiveIn patients with iron deficiency anaemia (IDA), the diagnostic yield of gastroscopy and colonoscopy (bidirectional endoscopy) in detecting neoplastic lesions is low. This study aimed to develop and validate a faecal immunochemical test (FIT)-based model to optimise the work-up of patients with IDA.MethodsOutpatients with IDA were enrolled in a prospective, multicentre study from April 2016 to October 2019. One FIT was performed before bidirectional endoscopy. Significant gastrointestinal lesions were recorded and a combined model developed with variables that were independently associated with significant colorectal lesions in the multivariate analysis. The model cut-off was selected to provide a sensitivity of at least 95% for colorectal cancer (CRC) detection, and its performance was compared to different FIT cut-offs. The data set was randomly split into two groups (developed and validation cohorts). An online calculator was developed for clinical application.ResultsThe development and validation cohorts included 373 and 160 patients, respectively. The developed model included FIT value, age, and sex. In the development and validation cohorts, a model cut-off of 0.1375 provided a negative predictive value of 98.1 and 96.7% for CRC and 90.7 and 88.3% for significant colorectal lesions, respectively. This combined model reduced the rate of missed significant colorectal lesions compared to FIT alone and could have avoided more than one-fourth of colonoscopies.ConclusionThe FIT-based combined model developed in this study may serve as a useful diagnostic tool to triage IDA patients for early endoscopic referral, resulting in considerable reduction of unnecessary colonoscopies.
Prevalence of hepatitis B and C virus infections among visceral leishmaniasis patients: a systematic review and meta-analysis
Authors: Assefa Muluneh , Biset Sirak 
Published: June 2024

BackgroundVisceral leishmaniasis (VL) patients are at high risk of acquiring hepatitis B virus (HBV) and hepatitis C virus (HCV) infections during multiple injections and the anti-leishmanial treatment possesses a potential hepatotoxic effect. This systematic review and meta-analysis determined the pooled prevalence of HBV and HCV infections in VL patients.MethodsThis study was registered in the International Prospective Register of Systematic Reviews (PROSPERO), with the assigned number CRD42024516889, and conducted as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search was performed using PubMed, Medline, EMBASE, Google Scholar, Web of Science, and Science Direct databases. Data were extracted using Microsoft Excel and analyzed using STATA version 11.0 software. A random-effects model was used to estimate the pooled effect size of outcome variables across studies with a 95% confidence interval and was displayed in a forest plot. The I2 statistic was used to check for heterogeneity. The presence of publication bias was determined using a funnel plot and Egger’s test with a p value &lt;0.05 evidence of statistically significant bias.ResultsAmong 216 retrieved records, seven studies were eligible for systematic review and meta-analysis. A total of 937 VL patients were examined, revealing that 105 and 93 were infected with HBV and HCV, respectively. The pooled prevalence of HBV was 16.15% (95% CI: −4.10 to 36.39), with a significant heterogeneity (I2 = 91.4%, p &lt; 0.001). The combined prevalence of HCV was 13.74% (95% CI: 1.32–26.16, I2 = 71.6%, p = 0.003). The funnel plot (symmetry), and Egger’s test in both HBV (p value = 0.650) and HCV (p value = 0.841) revealed no publication bias. In subgroup analysis, high HBV and HCV prevalence was detected in Sudan; 20.64% (95% CI: −13.60 to 54.88) and India; 18.26% (95% CI: −0.40 to 36.92%), respectively.ConclusionThis study revealed a high prevalence of both HBV and HCV infections in VL patients. In subgroup analysis, the prevalence of HBV and HCV was high in Sudan and India, respectively. Therefore, screening of VL patients for HBV and HCV, vaccination of VL patients in endemic regions, and collaboration between kala-azar and hepatitis elimination programs are required.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/export_details_pdf.php#page=1.00&amp;gsr=0, identifier: CRD42024516889.
Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis
Authors: Chu Xiangyu , Zhong Xiejian , Zang Shouge , Wang Mengting , Li Ping , Ma Yongsu , Tian Xiaodong , Yang Yanlian , Wang Chen , Yang Yinmo 
Published: June 2024

ObjectiveThe circulating tumor cells (CTCs) could be captured by the peptide functionalized magnetic nanoparticles (Pep@MNP) detection system in pancreatic ductal adenocarcinoma (PDAC). CTCs and the CXCR4 expression were detected to explore their clinical significance. The CXCR4+ CTCs, this is highly metastatic-prone stem cell-like subsets of CTCs (HM-CTCs), were found to be associated with the early recurrence and metastasis of PDAC.MethodsCTCs were captured by Pep@MNP. CTCs were identified via immunofluorescence with CD45, cytokeratin antibodies, and the CXCR4 positive CTCs were assigned to be HM-CTCs.ResultsThe over-expression of CXCR4 could promote the migration of pancreatic cancer cell in vitro and in vivo. In peripheral blood (PB), CTCs were detected positive in 79.0% of all patients (49/62, 9 (0–71)/2mL), among which 63.3% patients (31/49, 3 (0–23)/2mL) were HM-CTCs positive. In portal vein blood (PVB), CTCs were positive in 77.5% of patients (31/40, 10 (0–40)/2mL), and 67.7% of which (21/31, 4 (0–15)/2mL) were HM-CTCs positive CTCs enumeration could be used as diagnostic biomarker of pancreatic cancer (AUC = 0.862), and the combination of CTCs positive and CA19–9 increase shows improved diagnostic accuracy (AUC = 0.963). in addition, PVB HM-CTCs were more accurate to predict the early recurrence and liver metastasis than PB HM-CTCs (AUC 0.825 vs. 0.787 and 0.827 vs. 0.809, respectively).ConclusionsThe CTCs identified by Pep@MNP detection system could be used as diagnostic and prognostic biomarkers of PDAC patients. We identified and defined the CXCR4 over-expressed CTC subpopulation as highly metastatic-prone CTCs, which was proved to identify patients who were prone to suffering from early recurrence and metastasis.
The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients
Authors: Sun Ni , Li Ru , Deng Haiyi , Li Qingyang , Deng Jiaxi , Zhu Yue , Mo Wenwei , Guan Wenhui , Hu Minjuan , Liu Ming , Xie Xiaohong , Lin Xinqing , Zhou Chengzhi 
Published: June 2024

ObjectiveTo compare the prognostic differences between non-small cell lung cancer (NSCLC) patients with mild and severe checkpoint inhibitor-associated pneumonitis (CIP), and explore the causes of death and prognostic risk factors in NSCLC patients with severe CIP.MethodsA retrospective study of a cohort of 116 patients with unresectable stage III or IV NSCLC with any grade CIP from April 2016 to August 2022 were conducted. To analyze the clinical characteristics of patients with different CIP grades, patients were divided into mild CIP group (grade 1-2, n=49) and severe CIP group (grade 3-5, n=67) according to the grade of CIP. To explore the OS-related risk factors in the severe CIP group, the patients were divided into a good prognosis (GP) group (≥ median OS, n=30) and a poor prognosis (PP) group (&lt; median OS, n=37) based on whether their overall survival (OS) were greater than median OS. Baseline clinical and laboratory data were collected for analysis.ResultsThe median OS of all NSCLC patients combined with CIP was 11.4 months (95%CI, 8.070–16.100), The median OS for mild CIP and severe CIP was 22.1 months and 4.4 months respectively (HR=3.076, 95%CI, 1.904-4.970, P&lt;0.0001). The results showed that the most common cause of death among severe CIP patients in the PP group was CIP and the most common cause in the GP group was tumor. The univariate regression analysis showed that suspension of antitumor therapy was a risk factor for poor prognosis (OR=3.598, 95%CI, 1.307-9.905, p=0.013). The multivariate logistic regression analysis showed that suspension of anti-tumor therapy (OR=4.24, 95%CI, 1.067-16.915, p=0.040) and elevated KL-6 (OR=1.002, 95%CI, 1.001-1.002, p&lt;0.001) were independent risk factors for poor prognosis.ConclusionIn conclusion, patients with severe CIP had a poor prognosis, especially those with elevated KL-6, and the main cause of death is immune checkpoint inhibitor-associated pneumonitis complicated with infection. In addition, anti-tumor therapy for severe CIP patients should be resumed in time and should not be delayed for too long.